News

Wound Care Innovations, LLC, a subsidiary of Wound Management Technologies, Inc. (formerly MB Software Corporation) announced today that it will begin an evidence based study evaluating the clinical performance of their advanced wound care collagen product, CellerateRx® on skin tears. Skin tears represent a major problem in the elderly and compromised patients. It is estimated that at least 1.5 million skin tears occur in institutionalized patients(1) with prevalence rates between 14-24%.

"Skin tears can be a significant problem in the elderly due to loss of dermal tissue thickness, as well as other contributing factors such as comprised nutritional status and decreased mobility," said VP of Corporate Development Cathy Bradshaw. "Untreated skin tears can also serve as a portal of entry for local and systemic infection as well as a source of pain for the patient. Their treatment can have an impact on the facilities' financial resources and nursing time. We have had an excellent response from clinicians with Cellerate on skin tears and are looking forward to providing the medical community with evidence based data."

About Wound Management Technologies, Inc.:
Wound Management Technologies, Inc. (formerly MB Software Corp OTCBB: MBSB), with its corporate headquarters in Fort Worth, Texas, markets and distributes wound care products to the healthcare market under patented technology licensed to the Company. The Company is positioned and seeks to be a leading provider of wound care products.

For more information:
www.celleraterx.com

References:
(1) ECPN January 2007